. 2021 Sep 21;10(20):7162–7173. doi: 10.1002/cam4.4260

TABLE 1.

Confirmed ORR in patients with investigator‐assessed measurable or nonmeasurable but evaluable disease at baseline

Confirmed ORR, n/N (%) [95% CI]	BRCA mutated	HRD	ITT
Measurable disease at baseline ¹⁴	15/40 (37.5) [22.7–54.2]	2/23 (8.7) [1.1–28.0]	23/85 (27.1) [18.0–37.8]	3/41 (7.3) [1.5–19.9]	26/141 (18.4) [12.4–25.8]	5/66 (7.6) [2.5–16.8]
Nonmeasurable disease at baseline	12/38 (31.6) [17.5–48.7]	1/16 (6.3) [0.2–30.2]	16/66 (24.2) [14.5–36.4]	2/30 (6.7) [0.8–22.1]	23/104 (22.1) [14.6–31.3]	2/56 (3.6) [0.4–12.3]

Confirmed ORR, n/N (%) [95% CI]

BRCA mutated

HRD

ITT

Rucaparib

Placebo

Rucaparib

Placebo

Rucaparib

Placebo

Measurable disease at baseline ¹⁴

15/40

(37.5)

[22.7–54.2]

2/23

(8.7)

[1.1–28.0]

23/85

(27.1)

[18.0–37.8]

3/41

(7.3)

[1.5–19.9]

26/141

(18.4)

[12.4–25.8]

5/66

(7.6)

[2.5–16.8]

Nonmeasurable disease at baseline

12/38

(31.6)

[17.5–48.7]

1/16

(6.3)

[0.2–30.2]

16/66

(24.2)

[14.5–36.4]

2/30

(6.7)

[0.8–22.1]

23/104

(22.1)

[14.6–31.3]

2/56

(3.6)

[0.4–12.3]

Abbreviations: CI, confidence interval; HRD, homologous recombination deficient; ITT, intent to treat; ORR, objective response rate.